Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials

References

• Haffner SM Lehto S Ronnemaa T Pyorala K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 229 234 9673301
   PubMed Web of Science ®Google Scholar
• Simons LA Simons J Diabetes and coronary heart disease N Engl J Med 1998 339 1714 1715 9867543
   PubMed Web of Science ®Google Scholar
• Buse JB Bigger JT Byington RP Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods Am J Cardiol 2007 99 21i 33i
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Frye RL August P Brooks MM A randomized trial of therapies for type 2 diabetes and coronary artery disease N Engl J Med 2009 360 2503 2515 19502645
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Guzder RN Gatling W Mullee MA Mehta RL Byrne CD Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study Diabet Med 2005 22 554 562 15842509
   PubMed Web of Science ®Google Scholar
• Home PD Pocock SJ Beck-Nielsen H Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 373 2125 2135 19501900
   PubMed Web of Science ®Google Scholar
• Meyers CD McCarren M Wong ND Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial) Am J Cardiol 2006 98 63 65 16784922
   PubMed Web of Science ®Google Scholar
• Patel A Chalmers J Poulter N ADVANCE: action in diabetes and vascular disease J Hum Hypertens 2005 19 Suppl 1 S27 S32 16075030
   PubMed Web of Science ®Google Scholar
• The BARI 2 D Study Group Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial Am Heart J 2008 156 528 536 18760137
   PubMed Web of Science ®Google Scholar
• Viberti G Lachin J Holman R A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe Diabet Med 2006 23 1289 1294 17116177
   PubMed Web of Science ®Google Scholar
• Guidance for Industry Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 12 2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed March 29, 2013
   Google Scholar
• Fox CS Coady S Sorlie PD Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study Circulation 2007 115 1544 1550 17353438
   PubMed Web of Science ®Google Scholar
• van der Heijden AA Ortegon MM Niessen LW Nijpels G Dekker JM Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn study Diabetes Care 2009 32 2094 2098 19875606
   PubMed Web of Science ®Google Scholar
• Balkau B Hu G Qiao Q Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE study Diabetologia 2004 47 2118 2128 15662552
   PubMed Web of Science ®Google Scholar
• Davis WA Knuiman MW Davis TM An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study Intern Med J 2010 40 286 292 19323700
   PubMed Web of Science ®Google Scholar
• Kothari V Stevens RJ Adler AI UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine Stroke 2002 33 1776 1781 12105351
   PubMed Web of Science ®Google Scholar
• Stevens RJ Kothari V Adler AI Stratton IM The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) Clin Sci (Lond) 2001 101 671 679 11724655
   PubMed Web of Science ®Google Scholar
• Kengne AP Patel A Colagiuri S The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study Diabetologia 2010 53 821 831 20157695
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 2007 370 829 840 17765963
   PubMed Web of Science ®Google Scholar
• Erdmann E Dormandy JA Charbonnel B The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study J Am Coll Cardiol 2007 49 1772 1780 17466227
   PubMed Web of Science ®Google Scholar
• Wilcox R Bousser MG Betteridge DJ Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke 2007 38 865 873 17290029
   PubMed Web of Science ®Google Scholar
• Turnbull FM Abraira C Anderson RJ Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 2009 52 2288 2298 19655124
   PubMed Web of Science ®Google Scholar
• Lu SE Beckles GL Crosson C Evaluation of risk equations for prediction of short-term coronary heart disease events in patients with long-standing type 2 diabetes: the translating research into action for diabetes (TRIAD) study BMC Endocr Disord 2012 12 12 22776317
   PubMed Web of Science ®Google Scholar
• Zomer E Liew D Owen A Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham versus UKPDS algorithms Eur J Prev Cardiol 5 15 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Song SH Brown PM Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications Diabet Med 2004 21 238 245 15008833
   PubMed Web of Science ®Google Scholar
• Simmons RK Coleman RL Price HC Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC Norfolk Cohort Diabetes Care 2009 32 708 713 19114615
   PubMed Web of Science ®Google Scholar
• Davis WA Colagiuri S Davis TM Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study Med J Aust 2009 190 180 184 19220181
   PubMed Web of Science ®Google Scholar